article thumbnail

STAT+: Drug may make chemotherapies less effective in cancer patients with obesity — but many doctors are in the dark

STAT

This means chemotherapies may be less effective when interacting with the medicine, but some clinicians, and their patients, are unaware of that possibility. A drug used to combat fungal infections in cancer patients comes with a big caveat — research shows the medicine can last twice as long as in people with obesity.

article thumbnail

STAT+: Hair loss is one of the most hated chemotherapy side effects. A new biotech hopes to prevent it

STAT

The chemotherapy Christine Ko was prescribed for her breast cancer is pretty much a guarantee for losing your hair. The company is currently developing an antibody that might reliably protect the head’s hair follicles from chemotherapy damage — if it works. But, to her, it wasn’t much of an option.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: Merck, Daiichi Sankyo to partner on targeted chemotherapy drugs in deal worth up to $22 billion

STAT

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.     The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years.

article thumbnail

STAT+: FDA will allow troubled chemotherapy maker to resume distribution of cancer drugs in short supply

STAT

After finding a “cascade of failures” at a manufacturing plant run by a key chemotherapy supplier, the Food and Drug Administration will not allow the company to resume distribution in the U.S. beyond some   cancer medicines that are in short supply.

article thumbnail

STAT+: Incyte’s checkpoint inhibitor staves off disease progression in anal cancer trial

STAT

  The Phase 3 trial tested the PD-1 targeting antibody retifanlimab in combination with chemotherapy versus chemotherapy alone in patients with recurrent or metastatic squamous cell carcinoma of the anal canal. In the study, adding retifanlimab to chemotherapy cut the risk of disease progression or death by more than a third.

article thumbnail

STAT+: Gilead’s Trodelvy fails in lung cancer and raises new questions on antibody drug conjugate drugs

STAT

Gilead Sciences said Monday that Trodelvy, its “smart-bomb” medicine that combines an antibody with chemotherapy, did not significantly extend the lives of patients with metastatic non-small cell lung cancer when given after a first treatment failed. Continue to STAT+ to read the full story…

article thumbnail

STAT+: Roche drug slashes recurrence, death risk in lung cancer that afflicts younger patients

STAT

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday. The standard treatment after surgery for these patients is chemotherapy.